AREV Announces Significant Corporate Progress Amid Trading Suspension
VANCOUVER, BC – TheNewswire - February 6 , 2024 - AREV Life Sciences Global Corp. (CSE:AREV) (OTC:AREVF) (“AREV” or “the Company”) AREV Life Sciences is pleased to announce substantial corporate development during the recent trading suspension period underscoring our team's dedication to operations and innovation during this time.
The Company is pleased to report the successful completion of a pivotal transition in our audit and financial reporting processes. Our new auditing partners have completed an in-depth review of Arev's financials, resulting in the filing of our annual audit alongside three quarterly reports. By integrating and working with our audit partner’s financial processes and reporting, AREV is in full regulatory compliance and foresees regular reporting in the future as per requirements of the Canadian Stock Exchange.
During the trading suspension, Arev has not only maintained but accelerated its growth trajectory. In a strategic move designed to enhance our research and production capabilities, Arev has relocated its Research & Development (R&D) and Production facilities from Coquitlam to Salt Spring Island. The transition has already yielded promising outcomes, with the development of new formulations derived from our proprietary extracts of cucumaria frondosa, also known as the orange-footed sea cucumber. Extract formulations and innovations were focused on various advanced wound care applications, reducing inflammation and immunmodulation as sea cucumber extracts have untapped potential and undiscovered use in these applications.
Building on the momentum of our May 9, 2023 announcement, Arev has made forward strides in integrating artificial intelligence (AI) into its operations and optimizing formulas and combination therapies. Specifically, the Company has harnessed the latest 4.0 Plus functionalities from Open AI, the creators of Chat GPT, to develop a Custom Naturopathic Pharmacology Machine (NPM). This state-of-the-art AI tool is designed to meet Arev's specific research needs, enabling the creation of custom bots identifying efficacious molecules in approved drugs then match them to synergistic natural compounds with similar or complimentary mechanism of action to improve the efficacy, decreased toxicity, and reduced drug resistance of pharmaceuticals. With 21 versatile modes, AREV’s AI technology will revolutionize how the Company approaches formulations and Combination Therapy. Furthermore, using its AI technology, the company has already identified certain compounds and formulated proprietary compositions, including combination therapies with its sea cucumber extracts, that may improve pharmaceuticals in multiple ways and is reviewing patent applications with the guidance of its US patent attorneys.
The integration of AI into our research framework marks a significant milestone in our journey towards developing cutting-edge health solutions. The Company is now in the process of demonstrating its ability to innovate new biotechnology applications as the company has completed two preclinical in vivo studies and is waiting for the results of its third study. The results will be released over the coming weeks.
As we work towards resuming trading, AREV is more poised than ever to embark on the next phase of its growth. We are grateful for the continued support of our investors and the community, and we look forward to sharing our future successes in the near term.
For further information, contact Mike Withrow, firstname.lastname@example.org 778-896-6536. For more information visit www.arevlifesciences.com.
On behalf of the Board,
Michael C. Withrow
CEO & Director
About AREV Life Sciences Global Corp.
AREV Life Sciences Global Corp. strives for innovation in the quest for natural compounds and compositions for use in Combination Therapy to address select global health challenges of our time. With a fully integrated approach, the company specializes in the extraction of compounds for internal and topical application, the identification of advanced combination therapy techniques, and the implementation of a cutting-edge AI technology platform, the Naturopathic Pharmacology Machine.
Dedicated to producing pharmaceutical grade compounds and formulating exclusive therapeutic interventions, AREV leverages its core competency in extraction and separation technologies to fuel its pipeline of revolutionary therapeutic products. As a member of both BIOTECanada and The Biotechnology Innovation Organization (BIO), AREV Life Sciences Global Corp. aligns with the highest standards of excellence in biotechnological research, aiming to contribute meaningful solutions to pressing health issues while emphasizing sustainability and efficacy.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com.